Livius Penter Selected Research

Antigens

1/2023	Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease.
11/2022	Immune Phenotypes and Target Antigens of Clonally Expanded Bone Marrow T Cells in Treatment-Naïve Multiple Myeloma.
1/2019	Localization-associated immune phenotypes of clonally expanded tumor-infiltrating T cells and distribution of their target antigens in rectal cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Livius Penter Research Topics

Disease

9	Neoplasms (Cancer) 02/2024 - 12/2015
4	Leukemia 02/2024 - 10/2021
4	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2024 - 11/2021
2	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2023 - 12/2021
2	Multiple Myeloma 11/2022 - 01/2017
1	Myeloid Leukemia (Leukemia, Myelocytic) 02/2024
1	Squamous Cell Carcinoma of Head and Neck 01/2023
1	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2023
1	Virus Diseases (Viral Diseases) 11/2022
1	Infections 01/2022
1	Ovarian Epithelial Carcinoma 01/2022
1	Hypersensitivity (Allergy) 01/2022
1	Ovarian Neoplasms (Ovarian Cancer) 01/2022
1	Epstein-Barr Virus Infections 01/2022
1	Disease Progression 12/2021
1	Rectal Neoplasms (Rectal Cancer) 01/2019
1	Neuroblastoma 12/2015
1	Cardiomyopathies (Cardiomyopathy) 12/2015

Drug/Important Bio-Agent (IBA)

3	AntigensIBA 01/2023 - 01/2019
2	Proteins (Proteins, Gene)FDA Link 02/2024 - 01/2022
2	DNA (Deoxyribonucleic Acid)IBA 01/2023 - 12/2015
2	Mitochondrial DNA (mtDNA)IBA 01/2023 - 12/2021
2	IpilimumabIBA 01/2023 - 10/2021
2	MethyltransferasesIBA 01/2023 - 12/2015
2	Immune Checkpoint InhibitorsIBA 01/2023 - 01/2020
2	Neoplasm Antigens (Tumor Antigens)IBA 01/2023 - 01/2020
2	ChromatinIBA 01/2023 - 12/2021
2	Peptides (Polypeptides)IBA 11/2022 - 01/2022
1	Protein Isoforms (Isoforms)IBA 01/2024
1	Programmed Cell Death 1 ReceptorIBA 01/2023
1	Decitabine FDA Link 01/2023
1	HLA-C Antigens (HLA-C)IBA 11/2022
1	Immune Checkpoint ProteinsIBA 11/2022
1	Dexamethasone (Maxidex)FDA LinkGeneric 01/2022
1	HLA-A Antigens (HLA-A)IBA 01/2022
1	HLA-B Antigens (HLA-B)IBA 01/2022
1	Carboplatin (JM8)FDA LinkGeneric 01/2022
1	Paclitaxel (Taxol)FDA LinkGeneric 01/2022
1	Genetic Markers (Genetic Marker)IBA 12/2021
1	TransposasesIBA 12/2021
1	InterferonsIBA 11/2021
1	ChemokinesIBA 11/2021
1	NivolumabIBA 11/2021
1	VaccinesIBA 01/2020
1	Immunoglobulins (Immunoglobulin)IBA 01/2017
1	SGI-1027IBA 12/2015
1	F-Box ProteinsIBA 12/2015
1	Small Interfering RNA (siRNA)IBA 12/2015
1	Doxorubicin (Adriamycin)FDA LinkGeneric 12/2015
1	nanaomycin AIBA 12/2015
1	RG108IBA 12/2015

Therapy/Procedure

7	Therapeutics 02/2024 - 01/2017
4	Immunotherapy 10/2023 - 01/2020
2	Hematopoietic Stem Cell Transplantation 01/2023 - 11/2021
2	Neoadjuvant Therapy 01/2023 - 01/2022
1	Drug Therapy (Chemotherapy) 01/2022
1	Stem Cell Transplantation 01/2022
1	Transplantation 10/2021
1	Chemoradiotherapy 12/2015